International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform

The International Cancer Genome Consortium (ICGC) is further enabling cancer research worldwide by making a massive collection of cancer data available for analysis via Microsoft's Azure cloud computing platform. Providing secure, controlled access to ICGC genomic and clinical data on Azure will mitigate the need for researchers to obtain massive amounts of storage and computing power within their home institutions, meaning that more researchers will be able to use the data. The use of Azure was made possible by a philanthropic grant from Microsoft’s AI for Health program.

ICGC is a global collaboration that has generated comprehensive datasets of genomic mutations in more than 50 cancer types and made them available to researchers around the world to accelerate the development of next generation cancer treatments and diagnostics. The use of Azure will advance these efforts by providing cloud-based storage of ICGC data as well as a virtual computing platform to allow researchers to conduct data analysis in the cloud, using Azure-stored data or that from other ICGC platforms. Seven-hundred-fifty-four terabytes of ICGC data are available on Azure, comprising more than 75,000 files from 3,000 patient donors across 15 different cancer types.

"Through Azure we will put ICGC data into the hands of more scientists and remove the constraints that come with working with these large datasets. For example, even when using a high-speed internet connection, it can take researchers months to download the data they need. With Azure we've done away with that hurdle completely by taking the researcher's query to the data in the cloud," says Dr. Lincoln Stein, Head, Adaptive Oncology, Ontario Institute for Cancer Research and leader of the ICGC Data Coordination Center. "We are thankful for Microsoft's support and are grateful to the thousands of patients who donated the samples behind the data. We look forward to seeing the discoveries made using this new platform for ICGC data that will ultimately improve the lives of cancer patients."

"Cloud computing has the power to bring together researchers all over the world and advance scientific discoveries," says Geralyn Miller, Senior Director, Health Strategy, Microsoft AI for Good Research Lab. "The ICGC project is instrumental in the future of cancer research, and we are proud to help improve access to data for the global cancer research community through the AI for Health program."

ICGC has now moved into its next phase called ICGC ARGO (Accelerating Research in Genomic Oncology). ICGC ARGO will uniformly analyze specimens from 100,000 cancer patients with high quality clinical data to address outstanding questions that are vital to our quest to defeat cancer. It is anticipated that the Azure platform will be used to bring this incredibly valuable resource to the global cancer research community.

About the Ontario Institute for Cancer Research

OICR is a collaborative, not-for-profit research institute funded by the Government of Ontario. We conduct and enable high-impact translational cancer research to accelerate the development of discoveries for patients around the world while maximizing the economic benefit of this research for the people of Ontario. For more information visit http://www.oicr.on.ca.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...